iTeos Therapeutics (ITOS) IPO Opens 34% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- US stock index futures subdued as oil, Treasury yields rise on Iran tensions
- Oil prices steady as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Dollar hits two-week high, Middle East conflict and rate paths in focus
- Is the ECB’s hawkish shift just beginning to bite? UBS weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
iTeos Therapeutics Announces Pricing of Initial Public Offering
July 23, 2020 10:32 PM EDTCAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by iTeos. The shares are expected to begin trading on the Nasdaq Global Market on July 24, 2020 under the ticker symbol ITOS.  The gross proceeds of the offering, before deducting underwriting... More
